Patents by Inventor Tony Gibson

Tony Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2
    Publication number: 20220119361
    Abstract: Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R1, R2, R3, R4 and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.
    Type: Application
    Filed: April 28, 2020
    Publication date: April 21, 2022
    Inventors: Simone BIGI, Alison L. CHAMBERS, Tony GIBSON, Jason PICKENS, Steve SWANN, Angie VASSAR, Feng ZHOU, Mitsunori KONO, Masaki SETO, Zenyu SHIOKAWA
  • Heterocyclic compound
    Patent number: 9890145
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: February 13, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
  • HETEROCYCLIC COMPOUND
    Publication number: 20160311811
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: April 25, 2016
    Publication date: October 27, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masato YOSHIDA, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
  • Heterocyclic compound
    Patent number: 9321757
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: April 26, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
  • N-substituted oxazinopteridines and oxazinopteridinones
    Patent number: 9045496
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: June 2, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • HETEROCYCLIC COMPOUND
    Publication number: 20150133451
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 14, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshida, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
  • N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES
    Publication number: 20140309219
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • N-substituted oxazinopteridines and oxazinopteridinones
    Patent number: 8791107
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 29, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES
    Publication number: 20120220575
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong